Clinical Trial

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2017-05-11; most recent amendment 2026-01-29.
Status change: Recruiting → Active, Not Recruiting 2023-03-20
Status change: Not Yet Recruiting → Recruiting 2017-08-11
Trial Details
NCT Number NCT03153319
Lead Sponsor Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Enrollment 14 participants
Start Date 2017-06-05
Primary Completion 2027-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-02